ALTO stock icon

Alto Ingredients
ALTO

$1.56
1.3%

Market Cap: 120M

 

About: Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include major food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Other production. The Marketing and distribution segment participates in marketing and merchant trading for alcohols and essential ingredients; Pekin Campus produces and sells products produced at the company's Pekin, Illinois, campus, and about half of the firm's revenue flows from this segment. Other production makes and sells from the company's other production facilities.

Employees: 460

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

971% more call options, than puts

Call options by funds: $2.95M | Put options by funds: $275K

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

1% more funds holding

Funds holding: 101 [Q4 2023] → 102 (+1) [Q1 2024]

3% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 32

3.37% less ownership

Funds ownership: 42.83% [Q4 2023] → 39.45% (-3.37%) [Q1 2024]

25% less capital invested

Capital invested by funds: $86.7M [Q4 2023] → $65.1M (-$21.6M) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
156%
upside
Avg. target
$5
221%
upside
High target
$5.50
253%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Amit Dayal
253%upside
$5.5
Buy
Reiterated
7 May 2024
Craig-Hallum
Eric Stine
156%upside
$4
Buy
Maintained
12 Mar 2024
HC Wainwright & Co.
Heiko Ihle
253%upside
$5.5
Buy
Reiterated
12 Mar 2024

Financial journalist opinion